FIELD: chemistry.
SUBSTANCE: invention relates to compounds of general formula (I), as well as to pharmaceutically acceptable salts, enantiomers, diastereomer or racemates thereof. 
.
EFFECT: technical result: novel compounds having sigma receptor activity, that are useful for the treatment and/or prophylaxis of sigma mediated diseases or conditions.
8 cl, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMARKER ANALYSIS FOR DETECTING OR MEASURING TOR-KINASE ACTIVITY INHIBITION | 2011 |
|
RU2587040C2 |
| USE OF SIGMA LIGANDS WITH INDUCED OPIOIDS HYPERALGESIA | 2011 |
|
RU2589899C2 |
| USE OF SIGMA LIGANDS FROM PAIN IN BONE CANCER | 2011 |
|
RU2585095C2 |
| SIGMA-LIGANDS FOR APPLICATION IN PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | 2011 |
|
RU2569055C2 |
| METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| MTOR KINASE INHIBITORS FOR ONCOLOGIC INDICATIONS AND DISEASES ASSOCIATED WITH MTOR/PI3K/AKT BY METABOLISM | 2009 |
|
RU2692796C2 |
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| ESTROGEN RECEPTOR MODULATORS | 2017 |
|
RU2738646C2 |
| SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2417987C2 |
